
SGMT Stock Forecast & Price Target
SGMT Analyst Ratings
Bulls say
Sagimet Biosciences is a clinical-stage biopharmaceutical company recognized for its innovative portfolio of selective fatty acid synthase (FASN) inhibitors, notably the lead candidate denifanstat, which has shown significant anti-fibrotic effects and favorable lipid profile improvements in patients with nonalcoholic steatohepatitis (NASH). The company's recent advancements include receiving clearance for the IND application of TVB-3567, its second FASN inhibitor, which reinforces the potential for expanded revenue sources through tiered royalty payments from successful acne treatment outcomes. Overall, the positive data from clinical trials focusing on denifanstat's effects on liver health and cardiovascular markers supports a promising outlook for Sagimet Biosciences's stock, further underpinned by anticipated future product developments and market opportunities.
Bears say
Sagimet Biosciences reported a significant net loss of $16.2 million for the fourth quarter of 2024, translating to a loss of $0.50 per share, indicating challenges in financial performance that may deter investor confidence. The company faces multiple fundamental risks, including the potential for disappointing trial data for its lead drug candidate, denifanstat, as well as hurdles related to regulatory approvals and commercialization prospects, which could limit market opportunity. Additionally, operational funding concerns and possible intellectual property challenges further exacerbate the negative outlook for Sagimet’s stock, as these factors raise uncertainties surrounding the company's future prospects and overall viability.
This aggregate rating is based on analysts' research of Sagimet Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SGMT Analyst Forecast & Price Prediction
Start investing in SGMT
Order type
Buy in
Order amount
Est. shares
0 shares